Cardiac magnetic resonance shows a different heart motion in healthy obese compared to normal-weight volunteers

ISRCTN ISRCTN31812808
DOI https://doi.org/10.1186/ISRCTN31812808
Submission date
26/04/2021
Registration date
10/06/2021
Last edited
08/06/2022
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Circulatory System
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Background and study aims
Obesity is a major public health issue with nearly a third of the world population being classified as overweight or obese and has numerous adverse effects on cardiovascular (CV) health. Obese persons without CV disease might have already early manifestations of cardiac dysfunction without symptoms. The aim of our study is to explore heart motion and structure in healthy obese persons and the influence of a 6-month of reduced-carbohydrate (R-C) and reduced-fat (R-F) low calorie diet on heart motion and structure.

Who can participate?
Data collected during an earlier study (2007 - 2011) was used in this study. No new participants were included in the study.

What does the study involve?
Data were retrieved and analysed to explore heart motion and structure in healthy obese persons and the influence of a 6-month of reduced-carbohydrate and reduced-fat low calorie diet on heart motion and structure.

What are the possible benefits and risks of participating?
None

Where is the study run from?
Charité - University Medicine Berlin (Germany)

When is the study starting and how long is it expected to run for?
October 2019 to April 2021

Who is funding the study?
Investigator initiated and funded

Who is the main contact?
Dr med Edyta Blaszczyk, edyta.blaszczyk@charite.de

Contact information

Mrs Edyta Blaszczyk
Scientific

Charité University Medicine Berlin
Working Group Kardiale MRT Lindenberger Weg 80 Berlin
Berlin
13125
Germany

Phone +49 (0)30 450 540615
Email edyta.blaszczyk@charite.de

Study information

Study designRetrospective analysis
Primary study designObservational
Secondary study designCohort study
Study setting(s)Hospital
Study typeDiagnostic
Participant information sheet No participant information sheet available
Scientific titleMyocardial deformation and cardiac remodeling is influenced by obesity - assessment of myocardial strain by CMR feature tracking in healthy obese
Study acronymB-SMART (FT) CMR
Study objectivesThe study has two aims. Firstly, the researchers want to screen for cardiac remodeling in healthy obese persons by comparing them to healthy normal-weight persons. Secondly, they want to explore the influence of a 6-month of reduced-carbohydrate (R-C) and reduced-fat (R-F) hypocaloric diet on cardiac remodeling in healthy obese persons.
Ethics approval(s)Approved 28/05/2004, Ethical committee of the Charité Medical Faculty (Charité – Universitätsmedizin Berlin, Campus Charité Mitte, Charitéplatz 1, 10117 Berlin, Germany; +49 (0)30 450 517 222; ethikkommission@charite.de), ref: AA3/04/24
Health condition(s) or problem(s) studiedCardiac remodeling
InterventionThe analysis is part of the B-SMART Study (Berlin Study of Metabolomics in Adiposity and its Role for Successful Therapy) (ClinicalTrials.gov Identifier: NCT00956566). This prospective randomized study (April 2007 – December 2011) compared the effects of a 6-month hypocaloric diet with either reduced-carbohydrate (R-C) or reduced-fat (R-F) content on body weight reduction and metabolic and cardiovascular variables in 170 obese healthy women and men. 110 subjects completed the intervention phase and of those CMR imaging at 1.5T (Sonata and Avanto, Siemens Medical Solutions AG, Erlangen, Germany) at baseline and after diet could be obtained in 95 subjects. Of those, five subjects were excluded due to poor image quality at baseline or after diet, leaving a final intervention study cohort of 90 individuals, who were retrospectively analyzed using CMR feature tracking. Data was compared to 34 healthy non-obese volunteers (BMI <25 kg/m²). Post-processing was performed applying CVI42 (Version 4.1.2, Circle Cardiovascular Imaging Inc). Left ventricular (LV), right ventricular (RV), left atrial (LA), right atrial (RA) volume assessment was based on steady-state free precession (SSFP) cine images. Circumferential strain (CS) and radial strain (RS) were analyzed using short-axis views (SAX) and longitudinal strain (LS) using three long-axis (LAX) views. Strain was analyzed for each slide and each segment.
Intervention typeProcedure/Surgery
Primary outcome measureMyocardial deformation is measured by applying cardiac magnetic resonance feature tracking software (CVI42 (Version 4.1.2, Circle Cardiovascular Imaging Inc.)) at baseline and after 6 months
Secondary outcome measuresLeft atrial volume, right atrial volume, right ventricular volume, and left ventricular mass/volume ratio are measured at baseline and after 6 months. Units for volume are ml. Unit for left ventricular mass/volume ratio is g/ml. All secondary measures are collected by cardiac magnetic resonance data and are quantified by applying (CVI42 (Version 4.1.2, Circle Cardiovascular Imaging Inc.))
Overall study start date01/10/2019
Completion date30/04/2021

Eligibility

Participant type(s)Mixed
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participants124
Total final enrolment170
Key inclusion criteria1. Age >18 and <60 years
2. BMI >27 kg/m²
3. No medication except contraceptives or L-thyroxine
4. Discontinuation of a chronic medication must be medically justifiable because improvement in the condition for which the medication is being taken can be expected through weight loss
Key exclusion criteria1. Pregnancy/lactation
2. Diseases or functional disorders that, in the opinion of the investigator, preclude participation in a clinical trial
3. Manifest endocrinological or metabolic diseases requiring treatment (diabetes mellitus, hypo- and hyperthyroidism, Cushing's syndrome, M. Cushing syndrome, Cushing's disease); normal TSH with L-thyroxine use is acceptable
4. Manifest cardiovascular diseases requiring treatment (hypertension like RR > 160/95 mmHg or > two medications; coronary artery disease or previous myocardial infarction; cerebral ischemia or apoplexy; clinically significant diseases of the blood vessels (stenoses of the vessels supplying the brain; renal artery stenoses, pAVK)
5. Diseases of the kidney, liver, or gastrointestinal tract that require treatment and intestinal tract that require chronic medication
6. Significant neurological or psychiatric disorders (depression, epilepsy, schizophrenia, bulimia nervosa)
7. History of bariatric surgery
8. Known or proven abuse of medication, drugs or alcohol
9. Tumor diseases; postoperative phase
10. Acute and chronic infections
11. Incapacity or circumstances that do not allow the patient to fully understand the nature, meaning, and implications of this study
12. Metal implants and other contraindications by performing MRI (body weight > 130 kg)
Date of first enrolment01/04/2007
Date of final enrolment31/12/2011

Locations

Countries of recruitment

  • Germany

Study participating centre

Charité University Medicine Berlin
Campus Buch Working Group Kardiale MRT Lindenberger Weg 80
Berlin
13125
Germany

Sponsor information

Charité - University Medicine Berlin
University/education

Working Group Kardiale MRT Lindenberger Weg 80
Berlin
13125
Germany

Phone +49 (0)30 450 540615
Email jeanette.schulz-menger@charite.de
Website http://www.cmr-berlin.org
ROR logo "ROR" https://ror.org/001w7jn25

Funders

Funder type

Hospital/treatment centre

Charité – Universitätsmedizin Berlin
Private sector organisation / For-profit companies (industry)
Alternative name(s)
Medical School - Charité - University Medicine Berlin
Location
Germany

Results and Publications

Intention to publish date31/12/2021
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot expected to be made available
Publication and dissemination planResults of the study will be published in a high ranking peer-reviewed journal.
IPD sharing planThe datasets generated during and/or analysed during the current study are not expected to be made available due to confidentiality.

Editorial Notes

08/06/2022: Internal review.
21/05/2021: Trial's existence confirmed by Ethical committee of the Charité Medical Faculty.